2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Unknown
3
Sponsor Class
INDUSTRY
6
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
1
Multiple Myeloma
1
Leukemia, Myeloid
1
Interventions
Cyclophosphamide
2067
Radiotherapy
1990
Cisplatin
1856
Carboplatin
1560
Gemcitabine
1454
Paclitaxel
1320
Bevacizumab
1320
pembrolizumab
1237
Docetaxel
1227
Oxaliplatin
1184
Capecitabine
1176
Fluorouracil
1083
Dexamethasone
979
Magnetic Resonance Spectroscopy
971
Nivolumab
936
Rituximab
929
Drug Therapy
915
Surveys and Questionnaires
898
Doxorubicin
845
Etoposide
843
Radiosurgery
816
Blood Specimen Collection
816
Irinotecan
784
Cytarabine
743
fludarabine
726
Leucovorin
684
Surgical Procedures, Operative
639
Lenalidomide
618
Biopsy
594
fludarabine phosphate
569
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
Sensitivity and Specificity
×
Clear all
NCT04901364
2021-05-25
IPMN
Central Hospital, Nancy, France
Unknown
57 enrolled
NCT01864902
2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled
NCT01886976
2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled